284 related articles for article (PubMed ID: 24858067)
1. A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases.
Yanagawa H; Suzuki H; Suzuki Y; Kiryluk K; Gharavi AG; Matsuoka K; Makita Y; Julian BA; Novak J; Tomino Y
PLoS One; 2014; 9(5):e98081. PubMed ID: 24858067
[TBL] [Abstract][Full Text] [Related]
2. Clinical Significance of Serum Galactose-Deficient IgA1 Level in Children with IgA Nephropathy.
Irabu H; Shimizu M; Kaneko S; Inoue N; Mizuta M; Ohta K; Yachie A
J Immunol Res; 2020; 2020():4284379. PubMed ID: 32537466
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy.
Wada Y; Matsumoto K; Suzuki T; Saito T; Kanazawa N; Tachibana S; Iseri K; Sugiyama M; Iyoda M; Shibata T
PLoS One; 2018; 13(11):e0206865. PubMed ID: 30388165
[TBL] [Abstract][Full Text] [Related]
4. Significance of serum galactose deficient IgA1 as a potential biomarker for IgA nephropathy: A case control study.
Bagchi S; Lingaiah R; Mani K; Barwad A; Singh G; Balooni V; Bhowmik D; Agarwal SK
PLoS One; 2019; 14(3):e0214256. PubMed ID: 30917188
[TBL] [Abstract][Full Text] [Related]
5. A cross-sectional analysis of clinicopathologic similarities and differences between Henoch-Schönlein purpura nephritis and IgA nephropathy.
Sugiyama M; Wada Y; Kanazawa N; Tachibana S; Suzuki T; Matsumoto K; Iyoda M; Honda H; Shibata T
PLoS One; 2020; 15(4):e0232194. PubMed ID: 32324811
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of galactose-deficient immunoglobulin (Ig) A1 and related immune complex are associated with disease activity of IgA nephropathy.
Suzuki Y; Matsuzaki K; Suzuki H; Okazaki K; Yanagawa H; Ieiri N; Sato M; Sato T; Taguma Y; Matsuoka J; Horikoshi S; Novak J; Hotta O; Tomino Y
Clin Exp Nephrol; 2014 Oct; 18(5):770-7. PubMed ID: 24477513
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of galactose-deficient IgA are elevated in patients with IgA nephropathy but do not correlate to disease activity or progression.
Elíasdóttir S; Khramova A; Saeed A; Guron G; Boi R; Mölne J; Ebefors K; Nyström J
BMC Nephrol; 2023 Jun; 24(1):160. PubMed ID: 37286948
[TBL] [Abstract][Full Text] [Related]
8. Galactose-deficient IgA1 in African Americans with IgA nephropathy: serum levels and heritability.
Hastings MC; Moldoveanu Z; Julian BA; Novak J; Sanders JT; McGlothan KR; Gharavi AG; Wyatt RJ
Clin J Am Soc Nephrol; 2010 Nov; 5(11):2069-74. PubMed ID: 20634323
[TBL] [Abstract][Full Text] [Related]
9. Effect of Immunosuppressive Drugs on the Changes of Serum Galactose-Deficient IgA1 in Patients with IgA Nephropathy.
Kim MJ; Schaub S; Molyneux K; Koller MT; Stampf S; Barratt J
PLoS One; 2016; 11(12):e0166830. PubMed ID: 27930655
[TBL] [Abstract][Full Text] [Related]
10. Galactose-Deficient IgA1 as a Candidate Urinary Polypeptide Marker of IgA Nephropathy?
Suzuki H; Allegri L; Suzuki Y; Hall S; Moldoveanu Z; Wyatt RJ; Novak J; Julian BA
Dis Markers; 2016; 2016():7806438. PubMed ID: 27647947
[TBL] [Abstract][Full Text] [Related]
11. Glomerular Immunodeposits of Patients with IgA Nephropathy Are Enriched for IgG Autoantibodies Specific for Galactose-Deficient IgA1.
Rizk DV; Saha MK; Hall S; Novak L; Brown R; Huang ZQ; Fatima H; Julian BA; Novak J
J Am Soc Nephrol; 2019 Oct; 30(10):2017-2026. PubMed ID: 31444275
[TBL] [Abstract][Full Text] [Related]
12. Novel lectin-independent approach to detect galactose-deficient IgA1 in IgA nephropathy.
Yasutake J; Suzuki Y; Suzuki H; Hiura N; Yanagawa H; Makita Y; Kaneko E; Tomino Y
Nephrol Dial Transplant; 2015 Aug; 30(8):1315-21. PubMed ID: 26109484
[TBL] [Abstract][Full Text] [Related]
13. A Novel Biomarker for Post-Transplant Recurrent IgA Nephropathy.
Temurhan S; Akgul SU; Caliskan Y; Artan AS; Kekik C; Yazici H; Demir E; Caliskan B; Turkmen A; Oguz FS; Sever MS
Transplant Proc; 2017 Apr; 49(3):541-545. PubMed ID: 28340830
[TBL] [Abstract][Full Text] [Related]
14. Galactose-deficient IgA1 and the corresponding IgG autoantibodies predict IgA nephropathy progression.
Maixnerova D; Ling C; Hall S; Reily C; Brown R; Neprasova M; Suchanek M; Honsova E; Zima T; Novak J; Tesar V
PLoS One; 2019; 14(2):e0212254. PubMed ID: 30794576
[TBL] [Abstract][Full Text] [Related]
15. Clinical Significance of Galactose-Deficient IgA1 by KM55 in Patients with IgA Nephropathy.
Zhang K; Li Q; Zhang Y; Shang W; Wei L; Li H; Gao S; Yan T; Jia J; Liu Y; Lin S
Kidney Blood Press Res; 2019; 44(5):1196-1206. PubMed ID: 31574506
[TBL] [Abstract][Full Text] [Related]
16. Immunostaining for galactose-deficient immunoglobulin A is not specific for primary immunoglobulin A nephropathy.
Cassol CA; Bott C; Nadasdy GM; Alberton V; Malvar A; Nagaraja HN; Nadasdy T; Rovin BH; Satoskar AA
Nephrol Dial Transplant; 2020 Dec; 35(12):2123-2129. PubMed ID: 31369128
[TBL] [Abstract][Full Text] [Related]
17. Association of IgG co-deposition with serum levels of galactose-deficient IgA1 in pediatric IgA nephropathy.
Eison TM; Hastings MC; Moldoveanu Z; Sanders JT; Gaber L; Walker PD; Lau KK; Julian BA; Novak J; Wyatt RJ
Clin Nephrol; 2012 Dec; 78(6):465-9. PubMed ID: 23006340
[TBL] [Abstract][Full Text] [Related]
18. Serum galactose-deficient-IgA1 and IgG autoantibodies correlate in patients with IgA nephropathy.
Placzek WJ; Yanagawa H; Makita Y; Renfrow MB; Julian BA; Rizk DV; Suzuki Y; Novak J; Suzuki H
PLoS One; 2018; 13(1):e0190967. PubMed ID: 29324897
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers for IgA nephropathy on the basis of multi-hit pathogenesis.
Suzuki H
Clin Exp Nephrol; 2019 Jan; 23(1):26-31. PubMed ID: 29740706
[TBL] [Abstract][Full Text] [Related]
20. Measurement of galactosyl-deficient IgA1 by the monoclonal antibody KM55 contributes to predicting patients with IgA nephropathy with high risk of long-term progression.
Martín-Penagos L; Fernández-Fresnedo G; Benito-Hernández A; Mazón J; de Cos M; Oviedo MV; San Segundo D; López-Hoyos M; Gómez-Román J; Ruiz JC; Rodrigo E
Nefrologia (Engl Ed); 2021; 41(3):311-320. PubMed ID: 33741175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
